Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
Management will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with the Company's management team, please contact your Emerging Growth Conference representative or email the Company's investor relations team at PONTE VEDRA, Fla., July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the next Emerging Growth Conference, a virtual forum for institutional and retail investment community engagement.
美国佛罗里达州庞特韦德拉，2024年7月17日 /美通社/ -- Cadrenal Therapeutics公司（纳斯达克：CVDK）是一家生物制药公司，正在开发Tecarfarin，这是一种新一代的维生素K拮抗剂（VKA）口服可逆抗凝剂（血液稀释剂），旨在预防罕见心血管疾病患者因血栓引起的心脏病发作、中风和死亡。今天宣布，公司将参加下一个Emerging Growth Conference，这是一个为机构和零售投资社区提供虚拟交流的论坛。
Cadrenal's presentation will be on Thursday, July 18, 2024, at 4:15 pm ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed here.
Cadrenal的演讲将于2024年7月18日星期四下午4:15（ET）举行。演示文稿的网络广播链接可以在公司网站的投资者关系页面上找到或在此处访问。
If interested investors are not able to join the live event, an archived webcast will be available on and the Emerging Growth YouTube Channel, .
如果有兴趣的投资者无法参加现场活动，可以通过 Emerging Growth 的YouTube频道链接观看活动的存档网络广播。
Management will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with the Company's management team, please contact your Emerging Growth Conference representative or email the Company's investor relations team at [email protected].
在会议后，管理团队还将举行一对一的投资者会议。如果您想要请求与公司管理团队的虚拟一对一会议，请联系您的Emerging Growth Conference代表或发送电子邮件至公司投资者关系团队[email protected]。
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions who require lifelong anticoagulation. Tecarfarin has orphan drug designation from the FDA for the prevention of thrombosis and thromboembolism (blood clots) in patients with an implanted mechanical circulatory support device, which includes the left ventricular assist device (LVAD). Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to use a different metabolism pathway than the oldest and most commonly prescribed VKA warfarin. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: .
关于Cadrenal Therapeutics，Inc.
Cadrenal Therapeutics正在开发Tecarfarin以满足抗凝治疗的未满足需求。 Tecarfarin是一种新一代的维生素K拮抗剂(VKA)口服和可逆性抗凝剂(减薄机)，旨在预防罕见心血管疾病患者的心脏病发作、中风和死亡因血栓而引起的情况，在需要终身抗凝治疗的情况下。Tecarfarin已获得FDA的孤儿药标志，用于预防植入机械循环支持装置的患者的血栓和血栓栓塞(血栓) ，包括左室辅助装置(LVAD)。Tecarfarin还获得了FDA的孤儿药和快速通道标志，用于预防终末期肾病(ESKD)和心房颤动(AFib)患者的心源性全身性血栓栓塞。Tecarfarin采用与最古老和最常规处方的VKA华法林不同的代谢途径进行设计。 Tecarfarin已经进行了11项人体临床试验，涉及1000多名个体。在一期、二期和二期/三期临床试验中，Tecarfarin在健康成年受试者和慢性肾脏病患者中通常耐受良好。欲了解更多信息，请访问： .
For more information, please contact:
更多信息，请联系：
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
[email protected]
Cadrenal Therapeutics:
CFO马修·索特（Matthew Szot）
858-337-0766
[email protected]
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
[email protected]
投资者：
Lytham Partners, LLC
Robert Blum，管理合伙人
602-889-9700
[email protected]
SOURCE Cadrenal Therapeutics, Inc.
来源：Cadrenal Therapeutics，Inc。